Sirolimus Plus MEC Chemotherapy Has Significant Activity in High Risk AML Patients Especially Those Who Exhibit in Vivo Inhibition of the mTOR Pathway
Publication/Presentation Date
11-2012
Volume
120
Issue
21
First Page
143
Last Page
143
Published In/Presented At
Disciplines
Medicine and Health Sciences
Department(s)
Hematology-Medical Oncology Division
Document Type
Article
COinS